Tofacitinib shows safety comparable with biologics for PsA regarding serious infections, myocardial infarction or stroke, and malignancy but is tied to a higher risk for VTE than TNF inhibitors.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/safety-tofacitinib-vs-biologics-psoriatic-arthritis-one-risk-2026a1000awg?src=rss
Author :
Publish date : 2026-04-09 15:50:00
Copyright for syndicated content belongs to the linked Source.
